Cell and Gene Therapy Definitions for Raw Materials, Starting Materials, Drug Substance and Drug Product

Overview


Cell-and-Gene-Therapy-Definitions-for-Raw-Materials-Starting-Materials-Drug-Substance-and-Drug-Product.jpg

The complexity of processes to manufacture cell and gene therapy medicinal products can cause confusion around definitions of raw materials, starting materials, process intermediates, drug substance and drug products. This document will discuss the definitions of the above process components based upon statements to be found in recent regulatory guidance documents. Examples from cell and gene therapy processes will be given.

This content is provided by MilliporeSigma - Gene Therapy, and any views and opinions expressed do not necessarily reflect those of Biopharma-Reporter.com

Download Now


Related Resources

CDMO Process Development Template

CDMO Process Development Template

Content provided by MilliporeSigma - Gene Therapy

Infographic

Process development is a crucial step in viral vector manufacturing and a successful CDMO partnership can help navigate the challenges associated with scaling your viral vector.

Infographic - road map to commercialization

Infographic - road map to commercialization

Content provided by MilliporeSigma - Gene Therapy

Infographic

With the current increase in development and investment, gene therapy companies will increasingly be looking to streamline the manufacture and commercialization of their therapies.

Supplier Info Centre

MilliporeSigma-Gene-Therapy.png

For more product information visit MilliporeSigma - Gene Therapy.